文献速递细菌感染、耐药与抗菌药物

对1928-2021年27151株全球淋球菌基因组进行GyrB计算机挖掘并结合71株国际淋球菌分离株的唑利氟达星体外药敏检测,证实其高度敏感

GyrB in silico mining in 27 151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

研究查询欧洲核苷酸档案库中27151株淋球菌分离株(1928-2021年)的gyrB等基因序列,并对71株国际分离株进行唑利氟达星体外药敏检测。结果显示97.0%分离株GyrB为野生型,仅1株(0.0037%)携带耐药相关GyrB突变(D429V),其唑利氟达星MIC为8 mg/L。

要点

  • 97.0%的淋球菌分离株携带野生型GyrB序列,GyrB氨基酸改变罕见。
  • 仅1株(0.0037%)携带耐药相关GyrB突变(D429V),唑利氟达星MIC为8 mg/L。
  • 该耐药株分离自2000年日本男性患者,未克隆扩散或水平传播。

核心结论

  • 在27151株1928-2021年全球淋球菌分离株中,唑利氟达星靶点GyrB高度保守。
  • 唯一唑利氟达星耐药临床分离株(0.0037%)分离自2000年日本男性患者,该菌株未克隆扩散,gyrB耐药突变未通过水平基因转移传播。
  • 包括gyrB突变在内的唑利氟达星敏感性表型和基因组监测至关重要。

研究设计与样本

  • 研究查询欧洲核苷酸档案库(搜索词「Taxon: 485」),分析27151株淋球菌分离株的DNA序列,表征gyrB、gyrA、parC和parE等位基因。
  • 对71株具有不同GyrB、ParC和ParE替换的国际淋球菌分离株进行唑利氟达星体外药敏检测,在可行时测定相关唑利氟达星MIC。

主要发现

  • GyrB氨基酸改变罕见,97.0%的分离株具有野生型GyrB序列。
  • GyrB V470L是最常见的改变(占分离株的2.7%),其次为S467N(0.12%)、脑膜炎奈瑟菌GyrB(0.092%)、V470I(0.059%)、Q468R/P(0.015%)、A466T(0.0074%)、L425I+L465I(0.0037%)、L465I(0.0037%)、G482S(0.0037%)和D429V(0.0037%)。
  • 仅1株分离株(0.0037%)携带耐药相关GyrB密码子替换(D429V),其唑利氟达星MIC为8 mg/L。
  • 其他检测到的gyrB、gyrA、parC或parE突变均未导致唑利氟达星MIC超出野生型MIC分布。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a global threat and novel treatment alternatives are imperative. Herein, susceptibility to the novel antimicrobial zoliflodacin, currently in a global Phase 3 randomized controlled clinical trial for gonorrhoea treatment, was investigated by screening for zoliflodacin GyrB target mutations in publicly available gonococcal genomes and, where feasible, determination of the associated zoliflodacin MIC. METHODS: The European Nucleotide Archive was queried using the search term 'Taxon: 485'. DNA sequences from 27 151 gonococcal isolates were analysed and gyrB, gyrA, parC and parE alleles characterized. RESULTS: GyrB amino acid alterations were rare (97.0% of isolates had a wild-type GyrB sequence). GyrB V470L (2.7% of isolates) was the most prevalent alteration, followed by S467N (0.12%), N. meningitidis GyrB (0.092%), V470I (0.059%), Q468R/P (0.015%), A466T (0.0074%), L425I + L465I (0.0037%), L465I (0.0037%), G482S (0.0037%) and D429V (0.0037%). Only one isolate (0.0037%) carried a substitution in a resistance-associated GyrB codon (D429V), resulting in a zoliflodacin MIC of 8 mg/L. None of the other detected gyrB, gyrA, parC or parE mutations caused a zoliflodacin MIC outside the wild-type MIC distribution. CONCLUSIONS: The zoliflodacin target GyrB was highly conserved among 27 151 global gonococcal isolates cultured in 1928-2021. The single zoliflodacin-resistant clinical isolate (0.0037%) was cultured from a male patient in Japan in 2000. Evidently, this strain has not clonally expanded nor has the gyrB zoliflodacin-resistance mutation disseminated through horizontal gene transfer to other strains. Phenotypic and genomic surveillance, including gyrB mutations, of zoliflodacin susceptibility are imperative.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Golparian D, Jacobsson S, Sánchez-Busó L, et al. GyrB in silico mining in 27 151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility. J Antimicrob Chemother. 2022. PMID: 36308328. doi:10.1093/jac/dkac366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。